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Abstract  
3-iodothyronamine (T1AM) is a trace amine suspected to derive from thyroid hormone 
metabolism. T1AM was described as a ligand of  G-protein coupled monoaminergic 
receptors, including trace amine associated receptors, suggesting the amine may exert a 
modulatory role on the monoaminergic transmission. Nothing is known on the 
possibility that T1AM could also modulate the cholinergic transmission interacting with 
muscarinic receptors. 
We evaluated whether  T1AM (10 nM- 100 M) was able to i) displace [3H]-NMS 
(0.20 nM) binding to membrane preparations from CHO cells stably transfected with 
human muscarinic receptor subtypes (M1-M5);  ii) modify basal or acetylcholine 
induced pERK1/2 levels in CHO expressing the human muscarinic type 3 receptor 
subtype by Western blot iii)  modify basal and carbachol-induced contraction of isolated 
rat urinary bladder. T1AM fitting within rat muscarinic type 3 receptor was simulated 
by  Docking studies. 
T1AM recognized all muscarinic receptor subtypes (pKi values in the micromolar 
range). Interacting at type 3, T1AM reduced acetylcholine-increased pERK1/2 levels. 
T1AM reduced carbachol-induced contraction of the rat urinary bladder. The fenoxyl 
residue and the iodide ion were found essential for establishing contacts with the active 
site of the rat muscarinic type 3 receptor subtype. 
Our results indicate that T1AM binds at muscarinic receptors behaving as a weak, not 
selective, antagonist. This finding adds knowledge on the pharmacodynamics features 
of T1AM and it may prompt investigation on novel pharmacological effects of T1AM at 
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conditions of hyper-activation of the muscarinic tone including the overactive urinary 
bladder. 
 
Keywords: 3 –iodothyrothyronamine;  3-iodothyroacetic acid;  thyroid; muscarinic receptors. 
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1. Introduction 
3-iodothyronamine (T1AM) is an iodinated primary amine circulating in trace in  
human and rodents (Galli et al., 2012) (Saba et al., 2010). T1AM is produced in the 
thyroid as well as in extra-thyroid tissues (Hoefig et al., 2012) (Hoefig et al., 2015) and 
is rapidly metabolized by monoamine oxidases (MAO) and deiodinase activities to 3-
iodothyroacetic acid (TA1) and iodothyronamine, respectively  (Hackenmueller et al., 
2012). The physiological meaning of T1AM tissue levels is currently unknown. Much is 
instead known on the pharmacological effects of T1AM. In this respect, we described 
that T1AM acutely modifies mice behavior and metabolism (Manni et al., 2012) (Manni 
et al., 2013) (Laurino et al., 2015) with a mechanism which remains to be defined but 
that depends, at least in part, on the activation of the histaminergic system and on 
T1AM biotransformation into TA1 (Manni et al., 2012)(Manni et al., 2013) (Laurino et 
al., 2015).  In 2004, Scanlan et al.  described the hibernating effect of   T1AM while 
recently James et al (2013) reported a pro-awaking effect of T1AM in rats. 
Notwithstanding the increasing numbers of hypotheses,  the mechanisms responsible for 
such effects remain elusive yet.  
However, T1AM has the potential to interact at several targets as documented by 
different experimental approaches. Scanlan et al. (2004) described T1AM as an high 
affinity ligand (in the nanomolar range of affinity) for the trace amine-associated 
receptor type 1 (TAAR1). Later, by virtue of its -phenylethyl skeleton, in-vitro studies 
indicated T1AM recognized, in the micromolar range of concentrations, monoaminergic 
targets including beta 2 and alpha 2 receptors (Regards et al., 2007) (Dinter et al., 2015), 
working as an agonist and as an inverse agonist respectively (Dinter et al., 2015a 
)(Dinter et al., 2015b). More  recently,  Dinter et al. (2015)  reported T1AM as an 
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inverse agonist of TAAR type 5 (TAAR5) (Dinter et al., 2015c). Further, recent 
electrophysiological evidence indicated T1AM (in the range of 0.1-10 M) as an 
activator of the TRPM8 cold channel (Lucius et al., 2016). Except for alpha2 
adrenoceptors, whether any of these targets are involved in pharmacological effects of 
T1AM are currently unknown. This uncertainty also includes the involvement of 
TAAR1. In fact, Chiellini et al. (2005), reported findings which argued against the 
involvement of TAAR1 in T1AM-induced reduction of body temperature. However, the 
relationship between TAAR1 and T1AM  would merit to be further explored in light of 
the  findings from Szumska et al (2015). These authors reported TAAR1 expression on 
thyroid follicles, a localization supporting their role, and of T1AM, its endogenous 
ligand, in thyroid regulation. Taken together all these evidence indicate that T1AM, as 
other trace amines, may be considered a modulator of the monoaminergic transmission 
(Borowsky  et al., 2001).  Nothing is known instead about the possibility that T1AM 
could also modulate the cholinergic transmission interacting with muscarinic receptors. 
 Muscarinic receptors are a family of  five different G-coupled receptors (M1-M5) 
linked to  two main intracellular cascades governed by Gi or Gq proteins. Muscarinic 
receptors are expressed at the central nervous system, where they have a main role in 
memory and pain circuits, and in the periphery were they are involved in smooth muscle 
contraction, in exocrine and endocrine gland secretion, including the thyroid (Szumska 
et al., 2015) and the pancreas (Nakajima et al., 2013). The recognition of muscarinic 
receptors by T1AM might rationally sustain some pharmacological effects of the amine 
and open new perspectives for investigating unexplored T1AM functions governed by 
muscarinic signaling, including the control of visceral smooth muscle tone. 
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To explore this possibility we performed binding experiments with T1AM and with 
TA1 on human muscarinic receptor subtypes (M1-M5) stably expressed in CHO cells. 
Then, to investigate on the agonistic/antagonistic nature of T1AM  towards muscarinic 
receptors,  we evaluated whether T1AM modified i) basal or acetylcholine-induced 
pERK1/2 levels in CHO stably transfected with human muscarinic  type 3 receptor  and 
ii) basal or carbachol-induced contraction of the rat urinary bladder.  
2. Materials and methods  
2.1 Animals 
Male Sprague Dawley rats (275–300 g)  from ENVIGO (San Pietro al Natisone, Udine, 
Italy)  were used. Animals were kept at 23 ± 1°C with a 12 h light–dark cycle (light on 
at 07:00 h) and were fed a standard laboratory diet with water ad libitum.  
Experiments and animal use procedures were in compliance with ARRIVE guidelines 
(McGrath  et al., 2010). All the experimental procedures were in accordance with EU 
Directive 2010/63/EU for animal experiments. 
2.2Membrane preparation  
CHO cells stably expressing cDNA encoding the human muscarinic receptors (M1-M5) 
were generously provided by Prof. R. Maggio (Department of Experimental Medicine, 
University of L’Aquila, Italy).  
Confluent CHO cell lines were trypsinized, washed with buffer (25 mM sodium 
phosphate-containing 5 mM MgCl2 at pH 7.4) and homogenized for 30 s using an Ultra-
Turrax (16,000 rpm). The pellet was centrifuged (17,000 x g for 15 min at 4°C) and the 
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membranes were resuspended in the same buffer, re-homogenized with Ultra-Turrax 
and stored at −80°C until use. 
2.2 .1 Binding assay in CHO cells 
The radioligand binding assay was run in polypropylene 96-well plates (Sarstedt, 
Verona, Italy) and performed for 120 min at room temperature in a final volume of 0.25 
mL of 25 mM sodium phosphate buffer, pH 7.4, containing 5 mM MgCl2. Final 
membrane protein concentrations were: 30 μg/mL for human muscarinic type 1,  70 
μg/mL for human muscarinic type 2, 25 μg/mL for  human muscarinic type 3, 50 μg/mL 
for human muscarinic type 4  and 25 μg/mL for human muscarinic type 5. In 
heterologous competition curves, fixed concentrations of the tracer (0.2 nM [
3
H]-NMS, 
ca. KD) were displaced by increasing concentrations of T1AM and TA1 (Dei et al., 
2005). All measurements were performed in duplicate. At the end of the binding 
reaction, free radioligand was separated from bound ligand by rapid filtration through 
UniFilter GF/C plates (Perkin–Elmer Life and Analytical Science, Boston, MA, USA) 
using a FilterMate Cell Harvester (Perkin–Elmer Life and Analytical Science, Boston, 
MA); after filtration, the filters were washed several times with ice cold water, allowed 
to dry overnight at room temperature under air flow. 25 μl of scintillation liquid 
(Microscint-20, Perkin–Elmer Life and Analytical Science, Boston, MA) were then 
added and the filter-bound radioactivity counted by TopCount NXT Microplate 
Scintillation Counter (Perkin–Elmer Life and Analytical Science, Boston, MA). 
 
Off-Rate assays were performed to estimate the affinity of T1AM for the [
3
H]NMS 
occupied receptor. In these experiments, designed to investigate the effects of a range of 
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modulator concentrations on the [
3
H]NMS dissociation rate, a “one-point kinetic assay” 
approach was used, where the effect on radioligand dissociation of the test ligand was 
determined at 0 min and at one time point, which was chosen to be ca 2.5 dissociation 
half-lives of [
3
H]NMS alone (Lazareno et al., 1995). A high concentration of human 
M1-M5 CHO membranes (50-75 μg/ml) was incubated with a high concentration of 
[
3
H]NMS (2 nM) for about 60 min at room temperature. Then, 100 μl aliquots were 
distributed into tubes which contained 10 μl of 100 μM atropine alone, or in the 
presence of a different concentrations of test compounds, and diluted in 1 ml total 
volume of buffer. The time zero data point was obtained using only 100 μl of the 
mixture containing membranes plus [
3
H]NMS. Incubation (100 min for hM3) was 
terminated by rapid filtration through Whatman GF/C filters (Brandel, USA), that had 
been presoaked in a 0.05 % polyethylenimine (PEI) solution for at least 1 h, using a 
Brandell cell harvester (Biomedical Research and Development Laboratory, Inc Atlas 
Drive, Gaithersburg, MD, USA). Filters were washed three times with 3 ml aliquots of 
ice-cold milliQ water and dried before the addition of 4.5 ml of scintillation cocktail 
(Filter Count, Perkin-Elmer Life and Analytical Science, Monza, Italy). The 
radioactivity was determined using scintillation counting (TRI-CARB 1100, Perkin-
Elmer Life and Analytical Science, Monza, Italy). 
 
 
2. 3 Docking studies 
All derivatives were simulated in their protonated state, that one involved in ligand 
recognition by rat muscarinic type 3 receptor. The ligand’s conformational profile was 
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analyzed by MonteCarlo simulations which produced 1000 conformers by randomly 
rotating the rotatable bonds. In detail, the study was focused on the X-ray structure of 
the rM3R in complex with tiotropium (PDB Id: 4DAJ). The protein structure was 
prepared by removing the water molecules and all crystallization additives and then 
underwent energy minimation by keeping the backbone atoms fixed to preserve the 
resolved folding. After deleting the bound ligand, the so optimized protein structure was 
utilized by docking simulations as performed by using Plants which generates reliable 
ligand poses by ant colony optimization (ACO) algorithms (Korbe et al., 2009).  
In detail, the search was focused on a 10 Å radius sphere around the key aspartate 
residue (Asp147 in  rat muscarinic type 3 receptor) thus including the entire binding 
site; 10 poses were generated and scored by the ChemPlp function and the speed was 
equal to 1. The so obtained lowest score complex was minimized by keeping fixed all 
atoms outside a 10 Å radius sphere around the bound ligand and finally underwent a 
targeted 1 ns simulations with constant temperature at 300 K and the above mentioned 
constraints to assess the relative stability of the computed complex. All cited 
calculations were performed by using the conjugate gradient algorithm until a rms equal 
to 0.001. Namd2.9 was used with the CHARMM force field and the Gasteiger’s atomic 
charges  (Phillips et al., 2005).  
 
2.4. Western blot analysis 
For Western-blot analysis CHO cells transfected with human muscarinic type 3 receptor 
were cultured up to a sub-confluence density and then starved for 12 h in serum-free 
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medium. Cells were then washed 3 times with phosphate saline buffer (PBS), pH 7.4 
and exposed Ach as follows: 
To assess the effect of T1AM on basal pERK cell levels, cells were exposed to vehicle 
(Veh; i.e. DMSO 0.001-0.01% in H20) or T1AM (1, 10 µM prepared in Veh) for 5 min. 
To assess the stimulatory effect of acetylcholine, cells were pre-treated with atropine (1 
mM) and after 30 min, acetylcholine (3, 30, 100 and 1000 nM) was added and incubated 
further for 5 min with cells; 
To evaluate the effect of T1AM on acetylcholine-induced pERK1/2, cells were exposed 
to T1AM (1, 10 µM) for 10 min and then to acetylcholine (3, 30, 100 and 1000 nM ) for 
additional 5 min.  
After the last drug addition, cells were washed with PBS and scraped with 1% sodium 
dodecyl sulfate (SDS) and 1 mM EDTA to collect proteins. To note, CHO cell 
membranes do not possess cholinesterase activity (Gnagey et al., 1996)  and 
acetylcholine could therefore be used in the absence of a cholinesterase inhibitor. 
Furthermore, CHO cells do not express muscarinic receptors (Popper and Batra 1994). 
Because of this, experiments were only run on transfected CHO cells. Cell viability 
following exposure at each treatment was evaluated by the  (3-[4,5-dimethylthiazol-
2yl]-2,5-diphenyl tetrazolium bromide test (MTT; Mosmann, 1983). 
Cell proteins (20 μg) were separated on 10% SDS-PAGE and transferred into PVDF 
membranes (60 min at 398 mA) using standard procedures. Blots were incubated 
overnight at 4°C with specific antibody against ERK1/2, phosphorylated on 
Thr202/Tyr204 (Cell Signaling Technology, Denver, CO, USA) or GAPDH (Santa 
Cruz Biotechnology, Inc. Dallas, TX, USA) as reference protein. The antigen–antibody 
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complexes were visualized using appropriate secondary antibodies. Blots were 
immunorecognized for the proteins of interest using an enhanced chemiluminescence 
detection system (Pierce, Rodano, Italy). Exposition and developing time were 
standardized for all blots. Densitometric analysis of scanned images was performed on 
an iMac computer using the public domain NIH Image program. Results are expressed 
as arbitrary units (AU;  representing the ratio between the expression levels of the 
protein of interest normalized to that of GAPDH and considering this ratio as 1 in basal 
conditions) and they represent the mean ± S.E.M. of three different gels.   
2.5 Isolation of urinary bladder  
The urinary bladders were exposed, removed, and cleaned of connective tissue and 
adherent fat. The lowest half of the bladder was longitudinally bisected and used for in 
vitro studies. The urothelium–suburothelium was kept intact. The rat bladder was  
vertically mounted under 1.0 g resting tension in organ baths. Preparations were aerated 
with 95% O2 and 5% CO2 and bathed in a physiological salt solution of the following 
composition (mM): NaCl 119, KCl 4.7, NaHCO3 15, KH2PO4 1.2, MgCl2 1.2, CaCl2 
1.5, and glucose 11.1. Changes in isometric tension were recorded on a polygraph chart 
(Battaglia Rangoni, San Giorgio di Piano, Bologna, Italy. The KCl (80 mM)-induced 
increase in tension value was taken as 100% and the increase recorded in the presence 
of different concentrations of various drugs refer to this value. As contracting agent we 
used carbachol, the muscarinic agonist, at concentrations of 0.5, 5, 10 M and its 
responsiveness was not affected by previous exposure to high potassium solution (data 
not shown). T1AM cumulative concentrations (from 10 nM to 100 M) were added to 
the  carbachol concentration used.  
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2.6 Statistical analysis 
For radioligand inhibition binding experiments, a one-site binding equation was fitted to 
the specific binding of acetylcholine ligand to evaluate the IC50 which is the 
concentration of inhibitor that reduces half the maximal radioligand binding for 
acetylcholine binding site. IC50 values were converted to Ki values (inhibitor 
equilibrium dissociation constant) using the Cheng and Prusoff equation  (Lazareno et 
al., 1993). 
Data are expressed as mean ± S.E.M. of independent experiments. Statistical analysis 
was performed by one-way ANOVA. When the experimental setting included only two 
groups, the unpaired t-test was used. The threshold of statistical significance was set at 
P <0.05. All data analysis was performed by GraphPad Prism 5.02 statistical program 
(GraphPad Software, San Diego, CA, USA).  
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3. Results 
3.1 T1AM but not TA1 binds  to human muscarinic  receptors 
Binding experiments on human muscarinic receptor subtypes expressed in CHO cells 
were performed as described in the “Methods”  using [3H]NMS as radioligand. 
Our results showed that T1AM displaced [
3
H]NMS from all the 5 different human 
muscarinic receptor subtypes and a pKi value in the micromolar range was calculated 
(Table 1). In particular, T1AM showed similar pKi values for muscarinic type 1, type 3, 
type 4 and type 5 (Table 1; Fig. 1). Instead, the T1AM value of  affinity  towards 
muscarinic type 2 receptor was one order of magnitude lower than for other subtypes. 
These pKi values indicated a higher affinity of T1AM than that measured by carbachol, 
an agonist at muscarinic receptors (Table 1) which, as T1AM, did not show any 
preferential binding towards one specific muscarinic receptor subtype (Table 1).  
TA1, the acid derivative of T1AM, showed displacement of [
3
H]NMS from all the 
muscarinic receptor subtypes only at 1 mM concentration. Because of this, we 
considered the TA1 interaction at muscarinic receptors  irrelevant and not worth 
exploring further (data not shown). 
To determine the time course of [
3
H]NMS dissociation, preliminary assays in full time 
mode were performed as described in the Methods section. The mean rate of 
dissociation of [
3
H]NMS (koff) and the mean half-life of dissociation (t 1/2) was 
calculated for M3 receptor subtype (Table 2). Similar results were obtained for M1, M2, 
M4 and M5 receptor subtypes (data not showed). 
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Since [
3
H]NMS dissociation was found to follow a monoexponential time course, a one-
point kinetic protocol was applied. The residual binding of [
3
H]NMS at only one time 
point was measured in the absence and presence of different concentrations (0.01-100 
M) of the putative allosteric ligand (T1AM) and a single-point estimate of [3H]NMS 
(koff) was determined, to assess its potency in inhibiting the radioligand dissociation 
from the human M3 receptor subtype.  
Accordingly,T1AM di not  produce any effect on the dissociation of [
3
H]NMS, 
revealing its feature of only competitive ligand. 
 
 
3.2 T1AM interaction at human muscarinic type 3 receptor reduces acethylcholine-
induced pERK 1/2 levels 
Activation of ERK1/2 is recognized as a fingerprint of all muscarinic receptor subtype 
activation independently of the type of G protein coupled (Giovannini et al., 2015). In 
order to evaluate whether T1AM worked as an agonist or an antagonist at muscarinic 
receptors we chose to investigate the effect of T1AM on pERK1/2 levels in cell 
expressing human muscarinic type 3 receptor, the subtype for which T1AM showed the 
lowest pKi value (Table 1). Experiments were run in the absence and in the presence of 
acetylcholine.  
As shown in Fig. 2, when CHO cells transfected with human muscarinic type 3 receptor 
were exposed to T1AM (1, 10 M; Setting 1), pERK1/2  cell levels were similar to those 
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measured in control cells, not exposed to T1AM (Fig. 2, panels A), thus excluding that 
the amine can activate the intracellular cascade and thus work as an agonist. 
Instead, in the same cells, acetylcholine produced a concentration-dependent increase of 
pERK1/2  levels  (pEC50M  -7.81 ± 0.072). This increase was completely prevented 
when cells were pre-incubated with atropine (1M) for 25 min before exposure to 
acetylcholine (Fig. 3, panels a-d). Acetylcholine-induced increase of pERK1/2 levels  
was reduced by pre-incubating cells with T1AM. In this latter condition, the pEC50M  
values of Acetylcholine shifted to -6.96 ± 0. 11 and -6.67 ± 0.07 in the presence of 1 
and 10 M T1AM respectively. Higher concentrations of T1AM could not be tested 
because percentage of DMSO higher than 0.01%  reduced cell viability. 
These results were indicative of an antagonistic behavior of T1AM at human muscarinic 
type 3 receptor   
 
3.3 Docking studies indicate T1AM interactions at the active site of the rat  muscarinic 
type 3 receptor 
 
The putative complex of T1AM with the rat muscarinic type 3 receptor subtype was 
studied. Figure 3 shows that T1AM stabilizes a rich set of polar contacts involving the 
ligand ammonium head with Asp147 plus the surrounding tyrosine residues. In addition, 
the phenolic function elicited H-bonds with the conserved Thr231 and Thr234. When 
considering that the mentioned residues are highly conserved in all muscarinic subtypes, 
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such a common network of interactions could explain the affinity of the T1AM towards 
rat muscarinic type 3 receptor and, more generally, towards all muscarinic subtypes.  
Importantly, Fig. 3 emphasizes the stabilizing role of the iodine atom which is seen to 
elicit clear halogen bonds with Asn587 and Cys532 even though the steric clashes due 
to its marked atomic size tend to counterbalance the relevance of its contacts.  
The performed MD run confirms the notable stability of the computed complex as 
documented by the very low rmsd mean values of the bound ligand (2.21 ± 0.22 Å) and 
the surrounding residues (1.80 ± 0.17 Å).  Notably, the ion-pair with Asp147 and the 
halogen bond with Asn587 are stably retained throughout the simulation as evidenced 
by their distance averages (N+ - Asp147 = 2.90 ± 0.08 Å and I-Asn587 = 3.76 ± 0.29 
Å). In contrast, the H-bonds involving the phenolic group with Thr231 and Thr234 
shows a more dynamic behavior reasonably due to flexibility of the bound T1AM which 
assumes  progressively more extended conformations in order to maximize the p-p 
stacking contacts elicited by its aromatic rings.  
  
3.4 T1AM reduces carbachol-induced contraction of rat urinary bladder  
The rat urinary bladder expresses all subtypes of muscarinic receptors producing 
contractions of the detrusor muscle with the M3 subtype recognized as among the main 
involved in urinary bladder micturition. Accordingly, carbachol produced a 
concentration dependent increase of muscle contraction.  
T1AM (10 nM-100 M) was not able to modify rat bladder spontaneous contraction 
(data not shown) but instead it reduced carbachol-induced muscle contraction (Fig. 4) 
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and a  pIC50M value of -3.99 ± 0.29, -4.77±0.155 and -4.48±0.0.68 on 10, 5 and 0.5 
M carbachol respectively was calculated. T1AM (10 nM-100 M) did not modify 
KCl-induced (80 mM) contraction (data not shown). 
 
4. Discussion 
Our report on the capacity of T1AM, but not of TA1, to bind to all muscarinic receptor 
subtypes at the orthosteric site is a novel finding. In the range of concentrations 
consistent with pKi values calculated by binding experiments, T1AM reduces 
acetylcholine-induced pERK1/2 in CHO cells stably expressing the human type 3 
muscarinic receptor, the subtype chosen as prototype for studying T1AM 
pharmacodynamics features. Furthermore, in rat urinary bladder, a tissue expressing all 
the muscarinic receptors subtypes, T1AM reduces carbachol-induced contraction. Taken 
together our results indicate that T1AM behaves as a weak antagonist at muscarinic 
receptors. To the best of our knowledge this is the first evidence indicating a 
pharmacodynamics feature of T1AM translated into a functional effect.  
Our results recognize T1AM as a not selective ligand for muscarinic receptors. In fact, 
even if T1AM shows the lowest affinity for the type 2 than for the other subtypes, the 
differences among pKi values calculated from binding studies are not so high to 
consider the ligand as “selective” for one specific muscarinic subtype. This is not 
surprising since T1AM is an endogenous compound and because the amino acids lining 
the orthosteric binding site for muscarinic ligands are highly conserved among the five 
muscarinic subtypes (Wess et al., 2007)(Kruse et al., 2014).  This finding does not 
exclude that T1AM skeleton might serve to develop novel small-molecule orthosteric 
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ligands endowed with a high degree of selectivity for individual muscarinic subtypes, a 
goal which remains a major challenge for medicinal chemists. 
Since T1AM endogenous tissue levels are several orders of magnitude lower than those 
recognized to interact at muscarinic receptors (Laurino et al., 2015)(Manni et al., 2013) 
it is unlikely that  the antagonistic features on muscarinic receptors are part of the 
physiological role of T1AM. Instead, T1AM could have pharmacological effectiveness 
in reducing functional consequences of an hyper-activated muscarinic signaling. Among 
the functions controlled by the muscarinic pathway are the control of exocrine and 
endocrine gland secretion, including the thyroid and the pancreas, and of the smooth 
muscle tone (Maayan et al., 1983)(Montiel et al., 2007).   
However, we evaluated the anti-muscarinic features of T1AM in rat urinary bladder,  an 
ex-vivo model suitable for studying the effect of muscarinic and anti-muscarinic drug 
activities. In this preparation, all muscarinic subtypes are expressed and their activation 
evokes micturition. Consensus evidence indicates that the pharmacological effects 
mediated by the different subtypes are hard to distinguish (Hegde et al., 1997)  and that, 
in preparations from normal bladders with an intact urothelium, studies indicate that 
carbachol contraction is mediated by a homogenous muscarinic type 3 population 
(Hegde et al., 1997). In this tissue exposed to carbachol, mimicking increased 
cholinergic tone, we demonstrated that the addition of T1AM reduced contraction 
calculating an IC50M perfectly overlapping with pKi values measured from binding 
experiments. To note, T1AM does not modify basal rat bladder smooth muscle tone and 
it does not reduce KCl contraction. Importantly, the reduction of carbachol contraction 
is a typical effect of the amine and it does not involve the production of TA1.) 
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The present data contribute to the knowledge of the pharmacodynamics features of 
T1AM, confirming the amine is a low affinity ligand for several targets, among which 
the muscarinic receptors. These features potentially makes T1AM as an endogenous 
modulator of the aminergic and of the cholinergic transmission. From that it is known, 
T1AM has agonistic activity at alfa2 and behaves as an inverse agonist at beta2 
adrenoceptors, both features positively controlling the sympathergic transmission. To 
note, at very low doses, T1AM behaves as  a neuromodulator of the histaminergic 
system. 
To note, different portions of T1AM moiety are involved in the recognition of 
adrenergic and of muscarinic receptors. In fact, while the -phenylethyl moiety was 
recognized essential for interacting at adrenergic receptors, the diphenoxyl and iodide 
ion residues are here identified as crucial for establishing chemical connections with 
strategic amino acid residues in the active site of the muscarinic type 3 receptor which is 
however conserved among receptor subtypes and among species (Kruse et al., 2014). 
Furthermore, T1AM structure may represent a new fruitful chemotype to design novel 
anti-muscarinic drugs with higher affinity for the receptors than T1AM. In respect of the 
thyroid, anti-muscarinic drugs derived from T1AM might have some potential 
usefulness within the therapies for hyperthyroidism offering synergism  with drugs 
currently used to reduce hormone secretion.  
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Fig. 1 T1AM binds all human muscarinic receptor subtypes stably expressed in 
CHO cells. Plasma membranes were obtained from CHO cell expressing the 5 different 
human muscarinic receptor subtypes as described in the “Methods”. Membranes were 
probed with 0.2 nM [
3
H]-N-methyl-scopolamine and displacement was attempted by 
T1AM or TA1 (from 10 nM to 100 M). Results are the means±S.E.M.  of three 
experiments run in triplicate. 
Fig. 2 Acetylcholine activates ERK1/2 in CHO cells stably transfected with human 
muscarinic type 3 receptor subtype: the effect of atropine and of T1AM CHO Cells 
expressing human muscarinic type 3 receptor subtype  were exposed for 5 min to Panel 
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a: 3 nM acetylcholine  in the absence or in the presence of atropine (Atrop; 1M) or to 
T1AM (1, 10 and 100 M), Panel b:   10 nM acetylcholine in the presence or in the 
presence of atropine (Atrop; 1M) Panel c: to acetylcholine (30, 100, 1000 nM) in the 
presence or in the presence of atropine (Atrop; 1M)) or to T1AM (1, 10 M); 
Following exposure, cells were collected, lysed and analyzed for pERK1/2 cell levels as 
described in “Methods”. A densitometry analysis is reported (AU;  representing the 
ratio between the expression levels of the protein of interest normalized to that of 
GAPDH and considering this ratio as 1 in basal conditions) and they represent the mean 
± S.E.M. of three different gels. A  representative experiment for each acetylcholine 
concentration is shown.  Samples run on the gels derive from the same experiment and 
the  blots were processed in parallel. Panel d-: Concentration-effect curves of 
acetylcholine on pERK1/2 levels were built from results from densitometry. **P<0.01 
and ***P< 0.001 vs. Veh.; #P<0.05 , ##P<0.01, ###P<0.001 and #### P<0.0001 vs. 
acetylcholine. 
Fig. 3 Computed complex  of T1AM with rat muscarinic type 3 receptor subtype 
T1AM computed complex with rat muscarinic type 3 receptor subtype is showed 
Fig. 4 T1AM reduces carbachol-induced contraction of rat urinary bladder Rat 
urinary bladder was isolated as described in the “Methods” and put in an oxygenated 
organ bath. The rat urinary bladder was contracted by adding carbachol 0.5, 5 and 10 
M.  Cumulative concentration-response curves  of T1AM  (from 10 nM to 100 M) on  
each carbachol concentration were obtained.  Carbachol-induced contracture was 
measured (cm) and then compared to the contraction (cm) elicited by 80 mM KCl, taken 
as 100%. Results are expressed as the means ±S.E.M. of at least three different 
experiments for each  carbachol concentration. 
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Table 1 Affinity values of 3-iodothyronamine and carbachol binding  to human muscarinic 
receptors (M1-M5) 
 
 
 
Compounds 
 
Name 
 
hM1R 
 
hM2R 
 
hM3R 
 
hM4R 
 
hM5R 
 
T1AM 6.018 
±0.069 
5.119 
±0.098 
6.594 
±0.052 
6.184 
±0.071 
6.553 
±0.057 
 
Carbacho
l 
5.71 
±0.09 
5.49 
±0.06 
5.62 
±0.10 
5.04 
±0.07 
4.65 
±0.07 
 
Binding experiments were performed as described in “Methods” in plasma membrane of CHO cells 
stable transfected with human muscarinic  receptors (M1-M5). Each determination was run in 
triplicate and calculation of pKi was made by Graph-Pad fitting 
 
 
Table 2.  Dissociation rate constants of [
3
H]NMS in the absence and in the presence of T1AM 
obtained by single time point assays. 
  + T1AM (M) 
  1  10  100 Koff (min
-1) 0.018±0.002 0.019±0.002 0.016±0.001 0.017±0.001 
 
 
    
 
 
 
Values are shown as mean ± standard error of at least three experiments 
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